BBOT (BridgeBio Oncology Therapeutics) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.32
View Full Analysis

What is BridgeBio Oncology Therapeutics Other Stockholders Equity?

BridgeBio Oncology Therapeutics BBOT -8.72% 12 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

BridgeBio Oncology Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

BridgeBio Oncology Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then declined from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

BridgeBio Oncology Therapeutics's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

BridgeBio Oncology Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Other Stockholders Equity Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Stockholders Equity
-0.00 0.00 -0.00

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 -0.00
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
BridgeBio Oncology Therapeutics (BBOT) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Other Stockholders Equity too high?
BridgeBio Oncology Therapeutics' current Other Stockholders Equity is $-0.00 Mil. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Other Stockholders Equity compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.32
Price